Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042783 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Stage IV Melanoma
A Phase 2 study of Melanoma (Skin), sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Study locations
NCT00042783: Completed Phase 2 study of Melanoma (Skin), sponsored by SWOG Cancer Research Network.
NCT00042783 is a Phase 2 study of Melanoma (Skin) that has completed, run by SWOG Cancer Research Network. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00042783, a Phase 2 study of Melanoma (Skin), has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7
- Study locations
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine therapy may be effective in treating stage IV melanoma. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.
Conditions Studied
Interventions
- BIOLOGICAL D1/3-MAGE-3-His fusion protein
- BIOLOGICAL SB-AS02B adjuvant
Study Locations (7)
California
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Mississippi
- Veterans Affairs Medical Center - Biloxi - Biloxi
Oregon
- CCOP - Columbia River Oncology Program - Portland
Washington
- University of Washington School of Medicine - Seattle
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
What the finished NCT00042783 record still lists
NCT00042783 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 2 interventions - of which D1/3-MAGE-3-His fusion protein is the first listed.
NCT00042783 lists 7 locations in 6 states (California, Arizona, Michigan).
Frequently Asked Questions
What is clinical trial NCT00042783 about?
NCT00042783 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Vaccine therapy may be effective in treating stage IV melanoma. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma.
What is the current status of trial NCT00042783?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2006-03.
What conditions does trial NCT00042783 study?
This clinical trial studies the following conditions: Melanoma (Skin).
What interventions are being tested in trial NCT00042783?
The interventions under investigation include: D1/3-MAGE-3-His fusion protein (BIOLOGICAL), SB-AS02B adjuvant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00042783?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042783 being conducted?
This trial has 7 study locations across Arizona, California, Michigan, Mississippi, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
-
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
COMPLETED · Phase 2
-
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
COMPLETED · Phase 2
-
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia